Evidence map›Paper›PMID 26870344›Full record

ArticleBiomedical reports2016

Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice.

Fang-Fang Gao, Jia-Wei Lv, Ying Wang, Rong Fan, Qun Li, Zun Zhang, Lei Wei

Open access · bronzeAbstract read
In one paragraph

Article in Biomedical reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Genetic and Cellular Contributions to Liver Regeneration.Cold Spring Harbor perspectives in biology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Xiaotan Jieyu Prescription Alleviates Breast Precancerous Lesions through PI3K/Akt Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
  20. Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Fang-Fang GaoDepartment of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei 430071, P.R. China.
Jia-Wei LvZhongnan Hospital of Wuhan University, The Second College of Clinical Medicine of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Ying WangDepartment of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei 430071, P.R. China.
Rong FanDepartment of Physiology, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei 430071, P.R. China.
Qun LiRenmin Hospital of Wuhan University, The First College of Clinical Medicine of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Zun ZhangDepartment of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei 430071, P.R. China.
Lei WeiDepartment of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei 430071, P.R. China.
Wuhan University · CNRenmin Hospital of Wuhan University · CNZhongnan Hospital of Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinically, hepatotoxicity is an inevitable side effect during long-term endocrinotherapy in breast cancer patients. Various studies have reported the specific mechanism and protective methods for this long-term hepatotoxicity, however, the short-term influences of tamoxifen (TAM) on hepatocytes remain to be elucidated. The previous study investigated TAM-induced liver injury at the early stage of endocrine treatment. Mice were assigned into 2 groups: The experiment group was administrated with intraperitoneal (i.p.) injection of 6 mg/kg/day TAM for 2 weeks, and the control group was administrated with i.p. injection of physiological saline of the same dose. Body weights in each group were detected every day, and alanine aminotransferase and aspartate aminotransferase levels were measured every 3 days. Small pieces of the liver tissues were obtained and processed for protein extraction, biochemical detection and histopathological analysis 2 weeks later. The results indicated that TAM decreased the mice body weights. Morphologically, with the treatment of TAM for only 2 weeks, at the microscopic and ultrastructural levels the structure of hepatic cords became blurred in sections of the regions, although the lobules of the liver remained visible. Partially, hepatic cells were swelled in spherical shapes. Nuclei appeared to be pyknotic and exhibited uneven chromatin distribution. In addition, it was observed in the transmission electron microscopy analysis that nuclei became pyknotic and unevenly distributed. The majority of the nuclei were endowed with distinct heterochromatin and thick nucleoli. The mitochondrial cristae became vague and disorganized. Finally, western blotting was used and detected a significant increase of the caspase-3 level in the liver tissues. In conclusion, the experiments elucidated that TAM (6 mg/kg/day) would cause hepatotoxicity at the early stage of endocrine treatment in mice, and the underlying mechanism was involved with hepatocyte apoptosis.

Indexed as

breast cancerhepatotoxicityshort-term treatmenttamoxifen

Identifiers

PMID26870344
PMCPMC4726841
OpenAlexW1869171504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.